Top View
- Inhibition of Cytochrome P450 Enzymes
- Possible Involvement of Pregnane X Receptor–Enhanced CYP24 Expression in Drug-Induced Osteomalacia
- Biodiversity of P-450 Monooxygenase: Cross-Talk
- Psychiatry Pharmacogenetics Expanded Panel
- Pharmacogenomic Associations Tables
- Molecular Basis of Disease Cytochrome P450s in Humans Feb
- Differential Expression of Prostaglandin I2 Synthase Associated with Arachidonic Acid Pathway in the Oral Squamous Cell Carcinoma
- Cleveland Clinic Laboratories
- Dicloxacillin Induces CYP2C19, CYP2C9 and CYP3A4 in Vivo and in Vitro
- University of Groningen Regulation of Metabolizing Enzymes And
- CYP2C19, CYP2D6, CYP2C9, and VKORC1 Genetic Testing LCD ID
- The Impact of Cytochrome P450 2C19 Polymorphism on Cardiovascular
- Cafestol: a Multi-Faced Compound
- Your CYP2C19 Genetic Test Results and What They Mean
- Clinical Role of CYP2C19 Polymorphisms in Patients With
- Clopidogrel Therapy and CYP2C19 Genotype Laura Dean, MD1 Created: March 8, 2012; Updated: November 19, 2015
- Alternative Splicing in the Cytochrome P450 Superfamily Expands Protein Diversity to Augment Gene Function and Redirect Human Drug Metabolism S
- CYP2C19 Testing: an Opportunity to Improve Patient Care
- A Functional C–G Polymorphism in the CYP7B1 Promoter Region and Its Different Distribution in Orientals and Caucasians
- Prevalence of CYP2C19, CYP3A4 and FMO3 Genetic Polymorphisms in Healthy Northeastern Thai Volunteers
- Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs
- Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†
- Somatic Mutations in Arachidonic Acid Metabolism Pathway Genes Enhance Oral Cancer Post-Treatment Disease-Free Survival
- CYP2C19, CYP2D6, CYP2C9, and VKORC1 Genetic Testing (L35072)
- Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants
- Genetic Test of Cytochrome P450 2C19 (CYP2C19) for Clopidogrel Therapy
- A Review of the Important Role of CYP2D6 in Pharmacogenomics
- Genetic Polymorphism, Linkage Disequilibrium, Haplotype Structure and Novel Allele Analysis of CYP2C19 and CYP2D6 in Han Chinese
- Genetic Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard Populations: a Comparative Study
- CYP2C19 and CYP2C9: New Aspects of Pharmacogenetics and Transcriptional Regulation CYP2C19 and CYP2C9: Newof Pharmacogenetics Aspects and Transcriptional Regulation
- Pgx Recommendations by CYP2D6 Genotype CYP2D6 and Paroxetine
- Human Lanosterol 14-Alpha Demethylase (CYP51A1) Is a Putative Target for Natural Flavonoid Luteolin 7,30-Disulfate
- CYP2C19 Proton Pump Inhibitors Guideline Revised
- Multi-Ethnic Distribution of Clinically Relevant CYP2C Genotypes and Haplotypes
- CYP3A4 Induction by Rifampin: an Alternative Pathway for Vitamin D Inactivation in Patients with CYP24A1 Mutations
- Esomeprazole Therapy and CYP2C19 Genotype
- Genotyping of CYP2C19 Helps to Reassure Sufficient Effects of Antiplatelet Therapy in Combination with Proton Pump Inhibitors (Ppis)
- CYTOCHROME P450, FAMILY 2, SUBFAMILY C, POLYPEPTIDE 19 (CYP2C19) a Drug Metabolism Gene
- Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
- Cytochromes P , Drugs, and Diseases
- Development of a Fluorescence-Based Trypanosoma Cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease
- The Central Role of Cytochrome P450 in Xenobiotic Metabolism—A Brief Review on a Fascinating Enzyme Family
- CYP2C19 Gene Cytochrome P450 Family 2 Subfamily C Member 19
- Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype
- Antifungal Drugs
- Cytochrome P450: Implications for Human Breast Cancer (Review)
- Alternative Splicing in the Cytochrome P450 Superfamily Expands Protein Diversity to Augment Gene Function and Redirect Human Drug Metabolism S